Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPAC with Cisplatin and Doxorubicin in Recurrent Ovarian Cancer
NCT01809379Phase 2Completed
- Sponsor
- Ruhr University Bochum
- Start
- Feb 2013
- Primary completion
- Mar 2014
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin and doxorubicin in ovarian cancer, sponsored by Ruhr University Bochum. Primary endpoint: Clinical Benefit Rate at 6 months. Started Feb 2013; status: completed.
02
Drugs
cisplatindoxorubicin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT01809379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01809379.